ABSTRACTr: The effect of ivermectin or diethylcarbamazine (DEC) on Wuchereria bancrofti molting from the third to the fourth larval stage (L3 to L4) was evaluated in vitro. L3 larvae were harvested from laboratoryreared Aedes togoi 2 wk after feeding upon a microfilaremic human volunteer. The larvae were kept in an artificial medium (Franke's NI medium) with 10% human serum under an atmosphere of 5% CO2 for 20 days. Experimental tubes also contained ivermectin (0.1-1,000 ng/ml) or DEC (0.1-10,000 ng/ml). An estimated concentration of 50 ng/ml ivermectin inhibited molting in 50% of the larvae expected to molt. For DEC, this value was roughly 1,000 ng/ml. In this in vitro culture system, ivermectin inhibited the L3 to L4 molt of W. bancrofti and was roughly 20-fold more potent in this activity than DEC. Inclusion of the proportion of negative control larvae molting in the denominator of the % molt calculation eliminated effects of drug-independent inhibition of molt. In all experiments, this proportion ranged between 0.75 and 1.0, i.e., the proportion of larvae expected to molt in the absence of drug effects. Most L3 larvae in either test or control tubes were living when the experiment was terminated. Mortality specifically attributable to drugs was not documented. Figure 1 illustrates the dose-dependent inhibition of molting by ivermectin or DEC. Neither drug caused appreciable inhibition below 10 ng/ ml. The estimated dose for inhibiting molt among half the larvae was 50 ng/ml for ivermectin, and 1,000 ng/ml for DEC. As much as 500 ng/ml ivermectin was required to inhibit molt completely, and this occurred only at the highest concentration of DEC (10,000 ng/ml).
Just what the results in Figure 1 
